VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CERT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CERTCertara, Inc.
$7.17$1.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

CERT logoCertara, Inc.(CERT)Earnings, Financials & Key Ratios

CERT•NASDAQ
$7.17
Price updated Jul 7, 2026
SectorHealthcareIndustryHealthcare ITSub-IndustryLife Sciences and Precision Medicine Software
AboutCertara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.Show more
  • Revenue$419M+8.7%
  • EBITDA$78M+17.0%
  • Net Income-$2M+86.8%
  • EPS (Diluted)-0.01+86.7%
  • Gross Margin61.53%+2.8%
  • EBITDA Margin18.52%+7.6%
  • Operating Margin5.02%+1216.5%
  • Net Margin-0.38%+87.8%
  • ROE-0.15%+86.9%

CERT Price & Volume

Certara, Inc. (CERT) stock price & volume — 10-year historical chart

Loading chart...

Decelerating Growth Amidst Persistent Margin Volatility

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Decelerating
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Specialized labor cost inflation

Key Thesis Takeaways

  • Certara faces a challenging transition as revenue growth has slowed to 0.9% in 2026Q1, reflecting potential headwinds in the biotech sector that impact its project-based service model.
  • While the company has successfully deleveraged its balance sheet to a negligible $10.8 million in total debt, persistent stock-based compensation of $7.3 million in 2026Q1 continues to obscure underlying profitability.
  • Investors should monitor whether the firm can achieve sustainable operating leverage, as current SG&A expenses consume nearly all of the $50.7 million in quarterly gross profit.

Verdict Logic

while the balance sheet is healthy with a current ratio of 1.88, the lack of consistent GAAP profitability and the deceleration of top-line growth to 0.9% warrant a cautious wait-and-see approach.

CERT Growth Metrics

Certara, Inc. (CERT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years11.45%
3 Years7.66%
TTM6.4%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-475.28%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-505.06%

Return on Capital

10 Years0.14%
5 Years0.37%
3 Years-0.48%
Last Year1.48%

CERT Recent Earnings

Certara, Inc. (CERT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 11, 2026
Metric
Actual
Est
EPS
$0.09-18.2%
$0.11
Rev
$107M+0.7%
$106M
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$0.09-18.2%
$0.11
Rev
$104M+0.5%
$103M
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.14+27.3%
$0.11
Rev
$105M+1.3%
$103M
Q3 2025
Aug 6, 2025
Metric
Actual
Est
EPS
$0.07-30.0%
$0.10
Rev
$105M+0.5%
$104M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 11, 2026
$0.09vs $0.11-18.2%
$107Mvs $106M+0.7%
Q1 2026Feb 26, 2026
$0.09vs $0.11-18.2%
$104Mvs $103M+0.5%
Q4 2025Nov 6, 2025
$0.14vs $0.11+27.3%
$105Mvs $103M+1.3%
Q3 2025Aug 6, 2025
$0.07vs $0.10-30.0%
$105Mvs $104M+0.5%
Based on last 12 quarters of dataView full earnings history →

Latest CERT News

Recent stock market news and headlines for Certara, Inc. (CERT)

Globe News Wire·Jun 19, 2026
Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel and Squire, P. C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Certara (CERT) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Certara and would like to discuss your legal rights, call Bragar Eagel and Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.

GlobeNewsWire·Jun 19, 2026
Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Certara (CERT) To Contact Him Directly To Discuss Their Options

Globe News Wire·Jun 18, 2026
Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara's executive officers and whether investor losses may be recovered under federal securities laws.

GlobeNewsWire·Jun 18, 2026
Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara's executive officers and whether investor losses may be recovered under federal securities laws.

Peers Comparison

Key metrics vs top competitors for Certara, Inc. (CERT)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CERT logoCERTCertara, Inc.Current
$7.17$1.12B-717.008.75%-0.38%-0.15%—
MEDP logoMEDPMedpace Holdings, Inc.
$546.29$15.6B35.7519.97%17.19%120.89%—
IQV logoIQVIQVIA Holdings Inc.
$208.23$35.34B26.565.87%8.33%22.11%—
CRL logoCRLCharles River Laboratories International, Inc.
$228.68$11.01B-78.58-0.85%-4.59%-5.66%—
VEEV logoVEEVVeeva Systems Inc.
$192.30$31.24B35.3516.34%28.37%13.36%—
SLP logoSLPSimulations Plus, Inc.
$18.28$369.36M-5.6813.09%-77.96%-49.3%—

Compare CERT vs Peers

Certara, Inc. (CERT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MEDP

Most directly comparable listed peer for CERT.

Scale Benchmark

vs LLY

Larger-name benchmark to compare CERT against a more recognizable public peer.

Peer Set

Compare Top 5

vs MEDP, IQV, CRL, VEEV

CERT SEC Filings & Documents

Certara, Inc. (CERT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 15, 2026·SEC

Material company update

May 11, 2026·SEC

Material company update

Apr 22, 2026·SEC

10-K Annual Reports

4
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 11, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 6, 2025·SEC

Get notified when CERT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CERT Frequently Asked Questions

Certara, Inc. (CERT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Certara, Inc.'s revenue?

Certara, Inc. (CERT) reported $419.7M in revenue for fiscal year 2025. This represents a 156% increase from $163.7M in 2018.

How fast is Certara, Inc. growing?

Certara, Inc. (CERT) grew revenue by 8.7% over the past year. This is steady growth.

Is CERT profitable?

Certara, Inc. (CERT) reported a net loss of $15.1M for fiscal year 2025.

Dividend & Returns
What is CERT's return on equity?

Certara, Inc. (CERT) has a return on equity (ROE) of -0.2%. Negative ROE indicates the company is unprofitable.

What is Certara, Inc.'s free cash flow?

Certara, Inc. (CERT) generated $88.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in CERT back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →